Human Pathology
Volume 41, Issue 3 , Pages 401-406 , March 2010

Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and “triple-negative” breast cancers

  • Xiao Wang, MD, PHD

      Affiliations

    • Department of Breast Surgery, Jinan Central Hospital, Shandong University School of Medicine, Jinan 250013, China
    • Corresponding Author InformationCorresponding author. Department of Breast Surgery, Jinan Central Hospital, Shandong University School of Medicine, Jinan 250013, China.
    • Xiao Wang and Lan Chao contributed equally to this work.
    • ,
  • Lan Chao, MD, PHD

      Affiliations

    • Infertility Center, Qilu Hospital, Shandong University, Jinan 250012, China
    • Xiao Wang and Lan Chao contributed equally to this work.
    • ,
  • Xin Li, MD

      Affiliations

    • Department of Breast Surgery, Jinan Central Hospital, Shandong University School of Medicine, Jinan 250013, China
    • ,
  • Guohui Ma, MD

      Affiliations

    • Department of Breast Surgery, Jinan Central Hospital, Shandong University School of Medicine, Jinan 250013, China
    • ,
  • Liansheng Chen, MD

      Affiliations

    • Department of Breast Surgery, Jinan Central Hospital, Shandong University School of Medicine, Jinan 250013, China
    • ,
  • Yixiu Zang, MD

      Affiliations

    • Department of Breast Surgery, Jinan Central Hospital, Shandong University School of Medicine, Jinan 250013, China
    • ,
  • Gengyin Zhou, MD

      Affiliations

    • Department of Pathology, Shandong University School of Medicine, Jinan 250012, China

Received 28 July 2009 ,Revised 21 August 2009 ,Accepted 26 August 2009.

References 

  1. Wu GS. Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev. 2007;26:579–585
  2. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008;27:253–261
  3. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases-regulating the immune response. Nat Rev Immunol. 2007;7:202–212
  4. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–3290
  5. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999;97:575–586
  6. Thangaraju M, Kaufmann SH, Couch FJ. BRCA1 facilitates stress induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem. 2000;275:33487–33496
  7. Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI. Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer. 2000;89:177–186
  8. Yeh YT, Hou MF, Chung YF, et al. Decreased expression of phosphorylated JNK in breast infiltrating ductal carcinoma is associated with a better overall survival. Int J Cancer. 2006;118:2678–2684
  9. Griffin J. The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol. 2001;28(Suppl 17):3–8
  10. Miyamoto-Yamasaki Y, Yamasaki M, Tachibana H, Yamada K. Induction of endoreduplication by a JNK inhibitor SP600125 in human lung carcinoma A 549 cells. Cell Biol Int. 2007;31:1501–1506
  11. Perou CM, Solie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  12. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–8423
  13. Livasy CA, Karaca G, Nanda R, et al. Phenotype evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–271
  14. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–5374
  15. Parikh RR, Yang Q, Higgins SA, et al. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiation Oncology Biol Phys. 2008;70:35–42
  16. Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 2007;67:4459–4466
  17. Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol. 2004;66:1478–1490
  18. Mizuno R, Oya M, Shiomi T, Marumo K, Okada Y, Murai M. Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells. J Urol. 2004;172:723–727
  19. Codony-Servat J, Tapia MA, Bosch M, et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther. 2006;5:665–675
  20. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636
  21. Dalton LW, Pinder SE, Elston CE, et al. Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol. 2000;13:730–735
  22. Ching YP, Leong VY, Lee MF, et al. P21-Activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res. 2007;67:3601–3608
  23. O'Hagan RC, Hassell JA. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene. 1998;16:301–310
  24. Lee RJ, Albanese C, Fu M, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol. 2000;20:672–683
  25. Wulf GM, Ryo A, Wulf GG, et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 2001;20:3459–3472
  26. Pakunlu RI, Cook TJ, Minko T. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm Res. 2003;20:351–359
  27. Rudas M, Filipits M, Taucher S, et al. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat. 2003;81:149–157
  28. Levresse V, Marek L, Blumberg D, et al. Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells. Mol Pharmacol. 2002;62:689–697
  29. Zhou J, Liu M, Aneja R, et al. Reversal of p-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res. 2006;66:445–452
  30. Heasley LE, Han SY. JNK regulation of oncogenesis. Mol Cells. 2006;21:167–173

PII: S0046-8177(09)00322-0

doi: 10.1016/j.humpath.2009.08.018

Human Pathology
Volume 41, Issue 3 , Pages 401-406 , March 2010

Article Tools

* Image Usage & Resolution